Kent Lake PR LLC, a holder of 5.9% of the outstanding common stock of Quanterix Corporation, publicly announced its opposition to Quanterix's proposed merger with Akoya Biosciences on February 18, 2025. Kent Lake stated its belief that the merger agreement significantly undervalues Quanterix.
The shareholder expressed concerns that the merger would deplete nearly $100 million in net cash from Quanterix to 'bail out Akoya'. Kent Lake urged the Quanterix Board to abandon the merger and explore alternative paths, including refocusing on organic growth or pursuing a sale of Quanterix.
Kent Lake also declared its intention to take all necessary steps to vote against the deal, including potentially nominating directors to the Quanterix Board at the 2025 Annual Meeting. This opposition introduces significant uncertainty regarding the completion of the merger.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.